Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Trifecta Research Study

NCT07717866
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder, Suicidal Ideation
Interventions
Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine, Physiological Supplementation
Device · Drug
Lead sponsor
Axial Therapeutic Research
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 16, 2026, 10:10 PM EDT
Terminated Not applicable Interventional Results available

Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression

NCT02943096
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
CocoaVia, Placebo
Dietary Supplement · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Patient Characteristics and Cognitive vs. Behavioral Therapies for Depression

NCT04529694
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psychotherapy
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

Effects Of Antidepressants On Sexual Functioning In Adults

NCT00051272
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)

NCT01542229
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU), Treatment As Usual (TAU)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression

NCT01683019
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
NeoSync EEG Synchronization Therapy, Sham NeoSync EEG Synchronization Therapy
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 16, 2026, 10:10 PM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression

NCT04211467
View directory record Official record
Conditions
Depression, Clinical Depression, Depression, Anxiety, Depression, Postpartum, Depression, Endogenous, Depression in Remission, Depression Chronic, Depression Moderate, Depression Severe
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

NCT00385307
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
amibegron (SR58611A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 16, 2026, 10:10 PM EDT
Active, not recruiting Early Phase 1 Interventional

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

NCT04846829
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Improving Therapeutic Learning in Depression: Proof of Concept

NCT02376257
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
250 mg DCS, 100 mg Modafinil, Placebo
Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Terminated Phase 1 Interventional

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

NCT04951609
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Anaheim, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

NCT02960763
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 16, 2026, 10:10 PM EDT
Withdrawn Phase 4 Interventional

A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults

NCT01942187
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder Not Otherwise Specified (NOS)
Interventions
Aripiprazole, Bupropion, Problem Solving Therapy
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Pilot Study of Behavioral Activation for Prolonged Grief

NCT01556048
View directory record Official record
Conditions
Complicated Grief, Prolonged Grief Disorder, Major Depressive Disorder, Posttraumatic Stress Disorder
Interventions
Behavioral Activation
Behavioral
Lead sponsor
Anthony Papa
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 16, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dopamine Neurotransmission in Major Depression

NCT01659814
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Opioid Challenge Study

NCT02611752
View directory record Official record
Conditions
Moderate or Severe Opioid Use Disorder
Interventions
CAM2038
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Overland Park, Kansas • Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of CX157 (TriRima) for the Treatment of Depression

NCT00739908
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CX157 (TriRima), Placebo
Drug
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Beverly Hills, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Patient Tolerability Study of GSK163090

NCT00559299
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
GSK163090
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

NCT04032301
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Major Depressive Disorder
Interventions
Ketamine, Normal Saline
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

NCT01377194
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encino, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 16, 2026, 10:10 PM EDT
Not yet recruiting Phase 1 Interventional

Shortened LSD Intervention for Major Depressive Disorder

NCT07503002
View directory record Official record
Conditions
Major Depression Moderate, Major Depression Severe, Major Depression
Interventions
LSD, Risperidone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 10:10 PM EDT